Loading
NU Skin Enterprises, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Hatchett Steven Keith, was filed 12 Nov 2025.
NU Skin Enterprises, Inc.: what insiders have been doing
Headquartered in Provo, United States, NU Skin Enterprises, Inc. belongs to the Healthcare & Pharma sector and traces its origins to 1984. Filings by its managers are published through SEC (Form 4). Over the twelve months to 20 October 2026, 28 filings were filed, from 9 insiders.
The flow runs one way only: 1 insider bought (1 purchase totalling €46k) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €46k, the purchase published on 12 November 2025 by Hatchett Steven Keith is the largest of the period. On the buying side, the filings list 1 senior executive among the declarants.
The latest purchase dates back some time: it was published 343 days ago, on 12 November 2025. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (5,453 companies, median 22 filings), a count of 28 filings is above the norm. Our records for NU Skin Enterprises, Inc. go back to 2016, with 5 purchases and 136 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 1.49 bn USD and net income at 160.2 m USD.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
569
Thresholds
n/a
Buy Volume
€518,091
5 ops. · all time
Sell Volume
€133M
136 ops. · all time
Who traded when
BuySaleSteven Keith Hatchett2 buys
Chayce David Clark1 sale
Daniel W. Campbell1 sale
Emma S. Battle1 sale
Nathanson Laura1 sale
Since the insiders bought
- +4.0%Entry US$9.78 · Close at T+90 US$10.17
- +145.1%Entry US$20.71 · Close at T+365 US$50.76
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,765 of 26,283 companies
77.2
score / 100
Value96
Quality58
FCF yld19%
Earn yld66%
EV/EBITDA2.1x
ROE-33%
Gross mgn69%
Net mgn11%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.14
Analyst consensus
1 analysts0.00/5
US$12.77Target US$12.77(+148%)US$12.77
Income statement
RevenueUS$1.5B
Gross profitUS$1B69% margin
EBITDAUS$262.4M18% margin
Net incomeUS$160.2M-15.7% margin
Valuation
PER (trailing)5.1x
PER (forward)4.4x
P/Book0.5x
Beta0.90
Balance sheet & cash
Market capUS$250.2M
Total debtUS$306.6M
Free Cash FlowUS$46M
Debt / Equity53%
Profitability & ownership
ROE-32.5%
ROA3.4%
% insiders3.4%
% institutions76.7%
Last declaration on 10 September 2026
Declarations569 total
22 shares@ US$4.850.0000% mcap0.1% of flowClass A Common StockSEC:0001021561-26-000065:0
26,643 shares0Class A Common StockSEC:0001021561-26-000057:0
26,643 shares0Class A Common StockSEC:0001021561-26-000055:0
7,203 shares@ US$5.620.016% mcap100.0% of flowClass ASEC144:0001959173-26-004237
14 shares@ US$7.310.1% of flowClass A Common StockSEC:0001021561-26-000042:0
47,059 shares0Class A Common StockSEC:0001021561-26-000040:0
138,971 shares0Class A Common StockSEC:0001021561-26-000036:0
77,941 shares0Class A Common StockSEC:0001021561-26-000038:0
114,706 shares0Class A Common StockSEC:0001021561-26-000034:0
282,353 shares0Class A Common StockSEC:0001021561-26-000032:0
13,687 shares@ US$8.6366.1% of flowClass A Common StockSEC:0001021561-26-000030:0
45,502 shares@ US$8.6325.3% of flowClass A Common StockSEC:0001021561-26-000026:0
124,802 shares@ US$8.6321.6% of flowClass A Common StockSEC:0001021561-26-000022:0
28,602 shares@ US$8.6325.1% of flowClass A Common StockSEC:0001021561-26-000024:0
26,001 shares@ US$8.6313.0% of flowClass A Common StockSEC:0001021561-26-000028:0
11,725 shares@ US$8.369.9% of flowClass A Common StockSEC:0001021561-26-000014:0
1,534 shares@ US$8.367.1% of flowClass A Common StockSEC:0001021561-26-000020:0
10,763 shares@ US$8.365.2% of flowClass A Common StockSEC:0001021561-26-000018:0
17,947 shares@ US$8.369.6% of flowClass A Common StockSEC:0001021561-26-000016:0
49,037 shares@ US$8.368.2% of flowClass A Common StockSEC:0001021561-26-000012:0
2,910 shares0Class A Common StockSEC:0001021561-26-000010:0
8,952 shares0Class A Common StockSEC:0001021561-26-000008:0
15,667 shares0Class A Common StockSEC:0001021561-26-000006:0
9,847 shares0Class A Common StockSEC:0001021561-26-000004:0
42,970 shares0Class A Common StockSEC:0001021561-26-000002:0
25 of 569 declarations
About NU Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. (NYSE: NUS) is a U.S.-listed company on the New York Stock Exchange, headquartered in Provo, Utah, United States. Founded in 1984, the company grew out of a direct-selling model and has evolved into a global beauty and wellness platform that combines consumer brands, product innovation, and an affiliate-based distribution network. For investors, Nu Skin should be viewed as a specialized consumer-health and prestige-beauty franchise with exposure to anti-aging, preventive wellness, and social/digital commerce trends. ([nuskin.com](https://www.nuskin.com/in/en/site/company/about-us?utm_source=openai))\n\nThe business is organized around two principal product categories: beauty and wellness. Under the Nu Skin brand, the company sells skincare, personal care, and beauty device systems. Under Pharmanex, it offers nutritional supplements and wellness-oriented products. The ageLOC franchise is a core differentiator, spanning anti-aging skincare, connected beauty devices, and products positioned around healthy aging. Nu Skin emphasizes more than 40 years of scientific research, clinical substantiation, and innovation as part of its premium brand positioning and distributor appeal. ([ir.nuskin.com](https://ir.nuskin.com/news-releases/news-release-details/nu-skin-enterprises-announce-fourth-quarter-and-full-year-2025?utm_source=openai))\n\nNu Skin operates in nearly 50 markets worldwide, giving it a broad geographic footprint across Asia-Pacific, the Americas, Europe, and other international regions. That global reach supports revenue diversification and brand visibility, but it also introduces foreign-exchange volatility, local regulatory complexity, and uneven consumer demand across regions. In 2025, revenue was primarily generated by the beauty and wellness categories, while the Rhyz ecosystem contributed additional income through adjacent consumer, technology, and manufacturing activities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1021561/000114036126013156/ef20069502_ars.pdf?utm_source=openai))\n\nFrom a competitive standpoint, Nu Skin operates in a crowded landscape that includes multinational cosmetics groups, direct-selling peers, and digitally native consumer brands. Its competitive advantages lie in its long operating history, international affiliate base, premium product portfolio, and recurring product-launch cadence. Recent company disclosures show that fiscal 2025 results came in within guidance, and the company’s initial fiscal 2026 outlook points to a return to revenue growth by year-end. Recent notable initiatives include the launch of Prysm iO and continued expansion of ageLOC lines, signaling an ongoing effort to reignite organic growth and strengthen customer and affiliate retention. ([ir.nuskin.com](https://ir.nuskin.com/news-releases/news-release-details/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
